FibroGen amends debt agreement, reduces minimum cash requirement from $18.75M to $15M

KYNTRA BIO, INC.

Fourth Amendment to Financing Agreement with Morgan Stanley Tactical Value lenders executed August 12, 2025.
Minimum qualified cash balance reduced from $18.75 million to $15.0 million effective immediately.
Prior amendments dated May 8, June 5, and July 14, 2025 indicate ongoing covenant adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.